The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Abstract
The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan–Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7×10−5, hazard ratio (HR)=1.4), CDKN1B (P=5.4×10−5, HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Self-citationInternational Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Evaluation of gene expression measurements from commercial microarray platforms
Tan, P. K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg763 · Cited by 706
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
Huhtinen, K., Suvitie, P., Hiissa, J., Junnila, J., Huvila, J., Kujari, H., Setälä, M., Härkki, P., Jalkanen, J., Fraser, J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605011 · Cited by 297
Reles, A., Wen, W., Schmider, A., Gee, C., Runnebaum, I. B., Kilian, U., Jones, L. A., El‐Naggar, A. K., Minguillon, C., Schönborn, I., et al. (2001) · PubMed · Cited by 282
Sawada, K., Radjabi, A. R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A. R., Turkyilmaz, M. A., Salgia, R., Yamada, S. D., Vande Woude, G. F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1147 · Cited by 258
Mok, S. C., Bonome, T., Vathipadiekal, V., Bell, A., Johnson, M. E., Wong, K.-K., Park, D.-C., Hao, K., Yip, D. K. P., Donninger, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.018 · Cited by 255
Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.022 · Cited by 234
Ahmed, A. A., Mills, A. D., Ibrahim, A. E. K., Temple, J., Blenkiron, C., Vias, M., Massie, C. E., Iyer, N. G., McGeoch, A., Crawford, R., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.014 · Cited by 233
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer
Berchuck, A., Rodriguez, G. C., Kamel, A., Dodge, R. K., Soper, J. T., Clarke-Pearson, D. L., & Bast, R. C. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)80044-x · Cited by 231
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
Scambia, G., Testa, U., Benedetti Panici, P., Foti, E., Martucci, R., Gadducci, A., Perillo, A., Facchini, V, Peschle, C., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.71 · Cited by 198
The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer
Kamat, A. A., Fletcher, M., Gruman, L. M., Mueller, P., Lopez, A., Landen, C. N., Han, L., Gershenson, D. M., & Sood, A. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2338 · Cited by 170
Psyrri, A. K., Kassar, M., Yu, Z., Bamias, A., Weinberger, P., Markakis, S., Kowalski, D. P., Camp, R. L., Rimm, D. L., & Dimopoulos, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1436 · Cited by 166
Sims, A. H., Smethurst, G. J., Hey, Y., Okoniewski, M. J., Pepper, S. D., Howell, A., Miller, C. J., & Clarke, R. B. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-42 · Cited by 159
Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., & Bevilacqua, G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.38 · Cited by 153
Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer
Cooper, B. C., Sood, A., Davis, C. S., Ritchie, J., Sorosky, J., Anderson, B., & Buller, R. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02057-4 · Cited by 151
Bali, A., O’Brien, P. M., Edwards, L. S., Sutherland, R. L., Hacker, N. F., & Henshall, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0751 · Cited by 148
Nielsen, J. S., Jakobsen, E. H., Hølund, B., Bertelsen, K., & Jakobsen, A. K. M. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.14606.x · Cited by 147
BAX protein expression and clinical outcome in epithelial ovarian cancer.
Tai, Y., Lee, S., Niloff, E., Weisman, C., Ströbel, T., & Cannistra, S. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2583 · Cited by 135
Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy
van der Burg, M. E. L., Lammes, F. B., van Putten, W. L. J., & Stoter, G. (1988) · Gynecologic Oncology · doi:10.1016/0090-8258(88)90244-2 · Cited by 131
Sui, L., Dong, Y., Ohno, M., et al. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.2.315 · Cited by 128
Denkert, C., Budczies, J., Darb‐Esfahani, S., Győrffy, B., Sehouli, J., Könsgen, D., Zeillinger, R., Weichert, W., Noske, A., Buckendahl, A., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2547 · Cited by 126
Self-citationRubin, S. C., Finstad, C. L., Wong, G. Y., Almadrones, L., Plante, M., & Lloyd, K. O. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(12)90907-2 · Cited by 123
Farley, J. H., Smith, L. M., Darcy, K. M., Sobel, E. L., O’Connor, D., Henderson, B., Morrison, L. E., & Birrer, M. J. (2003) · PubMed · Cited by 118
Lassus, H. J. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.10.010 · Cited by 114
Rosen, D. G., Yang, G. S., Deavers, M. T., Malpica, A. L., Kavanagh, J. J., Mills, G. B., & Liu, J. (2006) · Cancer · doi:10.1002/cncr.21767 · Cited by 111
Reimer, D., Sadr, S., Wiedemair, A., Stadlmann, S., Concin, N., Hofstetter, G., Müller‐Holzner, E., Marth, C., & Zeimet, A. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0780 · Cited by 110
Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo, L., Katsaros, D., Scorilas, A., Fracchioli, S., Piccinno, R., de la Longrais, I. A. R., Howarth, D. J., & Diamandis, E. P. (2001) · PubMed · Cited by 105
Győrffy, B., Molnar, B. A., Lage, H., Szállási, Z., & Eklund, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005645 · Cited by 104
Self-citationSui, L., Dong, Y., Ohno, M., Sugimoto, K., Tai, Y., Hando, T., & Tokuda, M. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6308 · Cited by 103
Riedinger, J., Wafflart, J., Ricolleau, G., Eche, N., Larbre, H., Basuyau, J. P., Dalifard, I., Hacène, K., & Pichon, M.-F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl120 · Cited by 103
Lambeck, A. J. A., Crijns, A. P. G., Leffers, N., Sluiter, W. J., ten Hoor, K. A., Braid, M., van der Zee, A. G. J., Daemen, T., Nijman, H. W., & Kast, W. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1828 · Cited by 101
Schuyer, M., van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2101 · Cited by 95
Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., & Cristofani, R. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1181 · Cited by 88
Ferrandina, G., Legge, F., Martinelli, E., Ranelletti, F. O., Zannoni, G. F., Lauriola, L., Gessi, M., Gallotta, V., & Scambia, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602332 · Cited by 86
Interferon-γ expression is an independent prognostic factor in ovarian cancer
Marth, C., Fiegl, H., Zeimet, A. G., Müller‐Holzner, E., Deibl, M., Doppler, W., & Daxenbichler, G. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.007 · Cited by 85
Dong, Y., Walsh, M. D., McGuckin, M. A., Cummings, M. C., Gabrielli, B. G., Wright, R. G., Hurst, T., Khoo, S. K., & Parsons, P. G. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970822)74:4<407::aid-ijc8>3.0.co;2-z · Cited by 83
Widschwendter, A., Müller, H. M., Hubalek, M., Wiedemair, A., Fiegl, H., GOEBEL, G., Mueller‐Holzner, E., Marth, C., & Widschwendter, M. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.01.036 · Cited by 81
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer
Sillanpää, S. M., Anttila, M., Voutilainen, K., Ropponen, K. M., Turpeenniemi-Hujanen, T. M., Puistola, U., Tammi, R., Tammi, M., Sironen, R. K., Saarikoski, S., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.09.004 · Cited by 77
Rustin, G. J. S., Gennings, J. N., Nelstrop, A. E., Covarrubias, H., Lambert, H. E., & Bagshawe, K. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1667 · Cited by 76
Milde‐Langosch, K., Hagen, M., Bamberger, A., & ning, T. L. (2003) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200304000-00009 · Cited by 75
Baekelandt, M. M. O., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3775 · Cited by 74
Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
Masciullo, V., Scambia, G., Marone, M., Giannitelli, C., Ferrandina, G., Bellacosa, A., Panici, P. B., & Mancuso, S. (1997) · International Journal of Cancer · Cited by 73
Ross, J. S., Yang, F., Kallakury, B., Sheehan, C. E., Ambros, R. A., & Muraca, P. J. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.3.311 · Cited by 72
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Wang, Y., Helland, Å., Holm, R., Skomedal, H., Abeler, V. M., Danielsen, H. E., Tropé, C., Børresen-Dale, A.-L., & Kristensen, G. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601537 · Cited by 68
The clinical significance of pre‐operative serum CA 125 in ovarian cancer
Cruickshank, D. J., Fullerton, W. T., & Klopper, A. I. (1987) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1987.tb03177.x · Cited by 66
Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells
Dhar, K. K., Branigan, K., Parkes, J., Howells, R. E. J., Hand, P., Musgrove, C., Strange, R. C., Fryer, A. A., Redman, C. W. E., & Hoban, P. R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690826 · Cited by 65
CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer
Sevelda, P., SCHEMPER, M., & Spona, J. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90668-6 · Cited by 65
Methylation profile in benign, borderline and malignant ovarian tumors
Tam, K., Liu, V. W. S., Liu, S. S., Tsang, P. C. K., Cheung, A., Yip, A. M. W., & Ngan, H. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0178-5 · Cited by 64
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
Katsaros, D., Cho, W.-K., Singal, R., Fracchioli, S., de la Longrais, I. A. R., Arisio, R., Massobrio, M., Smith, M. W., Zheng, W., Glass, J., et al. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.018 · Cited by 62
Korkolopoulou, P. A., Vassilopoulos, I., Konstantinidou, A. E., Zorzos, H., Patsouris, E., Agapitos, E. B., & Davaris, P. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6627 · Cited by 60
Schmider, A., Gee, C., Friedmann, W. G., Lukas, J. J., Press, M. F., Lichtenegger, W., & Reles, A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5748 · Cited by 59
Gadducci, A., Cosio, S., FANUCCHI, A., Negri, S., Cristofani, R., & Genazzani, A. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.043 · Cited by 59
AGO-OVAR, F. T., Kommoss, S., du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., & Kommoss, F. K. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603531 · Cited by 54
p21WAF1/CIP1 protein expression in primary ovarian cancer.
Ferrandina, G., Stoler, A., Fagotti, A., Fanfani, F., Sacco, R., Pasqua, A. D., Mancuso, S., & Scambia, G. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.6.1231 · Cited by 54
Smith‐Sørensen, B., Kærn, J., Holm, R., Dørum, A., Trope, C. G., & Børresen‐Dale, A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.502 · Cited by 54
Baekelandt, M. M. O., Holm, R., Tropé, C. G., Nesland, J. M., & Kristensen, G. B. (1999) · PubMed · Cited by 52
Kudoh, K., Ichikawa, Y., Yoshida, S., Hirai, M., Kikuchi, Y., Nagata, I., Miwa, M., & Uchida, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10331 · Cited by 52
Khouja, M. H., Baekelandt, M. M. O., Nesland, J. M., & Holm, R. (2007) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31804216a0 · Cited by 52
A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma
Győrffy, B., Dietel, M., Fekete, T., & Lage, H. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01169.x · Cited by 52
Self-citationBrustmann, H. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.04.035 · Cited by 44
Darcy, K. M., Tian, C., & Reed, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4076 · Cited by 37
Secord, A. A., Lee, P. S., Darcy, K. M., Havrilesky, L. J., Grace, L. A., Marks, J. R., & Berchuck, A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.02.014 · Cited by 34
Using mitochondrial DNA as a biosensor of early cancer development
Birch‐Machin, M. A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602711 · Cited by 32
Cytoplasmic p27 Expression is an Independent Prognostic Factor in Ovarian Cancer
Duncan, T. J., Al‐Attar, A., Rolland, P., Harper, S., Spendlove, I., & Durrant, L. G. (2009) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181b64ec3 · Cited by 30
Levesque, M. A., Katsaros, D., Massobrio, M., Genta, F. T., Yu, H., Richiardi, G., Fracchioli, S., Durando, A., Arisio, R., & Diamandis, E. P. (2000) · PubMed · Cited by 30
Lee, Y. H., Heo, J. H., Kim, T. H., Kang, H., Kim, G., Kim, J., Cho, S.-H., & An, H. J. (2011) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3182063e71 · Cited by 29
Skírnisdóttir, I., Sorbe, B., Lindborg, K., & Seidal, T. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820986e5 · Cited by 29
Konstantinidou, A. E., Korkolopoulou, P. A., Vassilopoulos, I., Tsenga, A., Thymara, I., Agapitos, E. B., Patsouris, E., & Davaris, P. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00092-6 · Cited by 26
Green, J. A., Berns, E., Coens, C., van Luijk, I. F., Thompson-Hehir, J., van Diest, P. J., Verheijen, R. H. M., van de Vijver, M. J., van Dam, P., Kenter, G. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.015 · Cited by 25
Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours
Wisman, G. B. A., Hollema, H., Helder, M. N., Knol, A., der Meer, G. V., Krans, M., de Jong, S., de Vries, E. G. E., & van der Zee, A. G. J. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.5.1451 · Cited by 20
CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases
Tempfer, C. M., Hefler, L., Heinzl, H., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.636 · Cited by 19
Psyrri, A. K., Yu, Z., Bamias, A., Weinberger, P., Markakis, S., Kowalski, D. P., Camp, R. L., Rimm, D. L., & Dimopoulos, M. A. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0120 · Cited by 11
Expression and Prognostic Significance of Cyclin D3 in Ovarian Adenocarcinomas
Levidou, G., Korkolopoulou, P. A., Thymara, I., Vassilopoulos, I., Saetta, A. A., Gakiopoulou, H., Konstantinidou, A. E., Kairi-Vassilatou, E., Pavlakis, K., & Patsouris, E. (2007) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31804630a7 · Cited by 10
Cited by
Lánczky, A., & Győrffy, B. (2021) · Journal of Medical Internet Research · doi:10.2196/27633 · Cited by 1,694
Self-citationEndogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement
Goodarzi, H., Liu, X., Nguyen, H. C. B., Zhang, S., Fish, L., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2015.02.053 · Cited by 949
Lánczky, A., Nagy, Á., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 768
Self-citationNetwork-based stratification of tumor mutations
Hofree, M., Shen, J. P., Carter, H., Gross, A., & Ideker, T. (2013) · Nature Methods · doi:10.1038/nmeth.2651 · Cited by 737
Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1256 · Cited by 373
Metadata
- Authors
- Győrffy, B., Lánczky, A., & Szállási, Z.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-01-25
- Volume
- 19
- Issue
- 2
- Pages
- 197-208
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2143017330
- Cited by
- 970
- References
- 81
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.